Anticoagulant therapy and components of the metabolic syndrome in patients with atrial fibrillation in real outpatient clinical practice
https://doi.org/10.21518/2079-701X-2019-5-60-63
Abstract
The aim of the study was to determine the prevalence of atrial fibrillation (AF) in patients hospitalized in the therapeutic and cardiology departments of the St. Petersburg hospital, and to analyze the prevalence of the number of components of the metabolic syndrome (MS) in patients with AF and anticoagulant therapy (ACT) assigned to outpatient stage to hospitalization. A retrospective analysis of 1760 case histories of patients hospitalized in the therapeutic and cardiology departments of the Therapy Clinic of the Faculty of Pavlov State Medical University named after IP Pavlov for 2017 was performed. It was established that AF was found in 16.5% (286) patients hospitalized in 2017. Among the causes of AF in patients, the number of components of MS was analyzed: 0 – 2.1% (6), 1 – 4.5% (13), 2 – 19.2% (55), 3 – 34.3% (98), 4 – 31.5% (90), 5 – 8.4% (24), thus MS with 3 or more components installed in 74.1% (212) surveyed in 2017. 58.7% (168) received ACT at the time of hospitalization, and 41.3% did not receive it (118). In 32,9% of patients with AF did not receive anticoagulant therapy at the prehospital stage, with no contraindications for administration. Among patients receiving ACT at the time of hospitalization, direct oral anticoagulants were prescribed 2 times more often than warfarin (69% and 31%, р = 0,01).
About the Authors
V. A. Ionin
Federal State Budgetary Educational Institution of Higher Education «Academician I.P. Pavlov First St. Petersburg State Medical University» of the Ministry of Healthcare of Russian Federation; Federal State Budgetary Institution «Almazov National Medical Research Center» of the Ministry of Health of the Russian Federation.
Russian Federation
Russian Federation
Ionin Valery Aleksan drovich – Dr. of Sci.(Med.), Assistant of Lang Chair of Intermediate Level Therapy.
197022, Russia, St. Petersburg, Lva Tolstogo St., 6-8 ; 197341, Russia, St. Petersburg, Akkuratova St., 2.
E. Yu. Petrischeva
Federal State Budgetary Educational Institution of Higher Education «Academician I.P. Pavlov First St. Petersburg State Medical University» of the Ministry of Healthcare of Russian Federation.
Russian Federation
Russian Federation
Petrischeva Elena Yurievna – Resident Medical Practitioner of Lang Clinic of Intermediate Level Therapy.
197022, Russia, St. Petersburg, Lva Tolstogo St., 6-8.
D. S. Skuridin
Federal State Budgetary Educational Institution of Higher Education «Academician I.P. Pavlov First St. Petersburg State Medical University» of the Ministry of Healthcare of Russian Federation.
Russian Federation
Russian Federation
Skuridin Daniil Sergeevich – Resident Medical Practitioner of Lang Clinic of Intermediate Level Therapy.
197022, Russia, St. Petersburg, Lva Tolstogo St., 6-8.
O. I. Bliznyuk
Federal State Budgetary Educational Institution of Higher Education «Academician I.P. Pavlov First St. Petersburg State Medical University» of the Ministry of Healthcare of Russian Federation.
Russian Federation
Russian Federation
Bliznyuk Olga Igorevna – a fourth year student of Lang Chair of Intermediate Level Therapy.
197022, Russia, St. Petersburg, Lva Tolstogo St., 6-8.
A. A. Ivanova
Federal State Budgetary Educational Institution of Higher Education «Academician I.P. Pavlov First St. Petersburg State Medical University» of the Ministry of Healthcare of Russian Federation.
Russian Federation
Russian Federation
Ivanova Anna Andreevna – a sixth year student of Lang Chair of Intermediate Level Therapy.
197022, Russia, St. Petersburg, Lva Tolstogo St., 6-8.
A. E. Filatova
Federal State Budgetary Educational Institution of Higher Education «Academician I.P. Pavlov First St. Petersburg State Medical University» of the Ministry of Healthcare of Russian Federation.
Russian Federation
Russian Federation
Filatova Alina Evgenievna – a sixth year student of Lang Chair of Intermediate Level Therapy.
197022, Russia, St. Petersburg, Lva Tolstogo St., 6-8.
I. Ma.
Federal State Budgetary Institution «Almazov National Medical Research Center» of the Ministry of Health of the Russian Federation.
Russian Federation
Russian Federation
Ma I. – Cand. of Sci. (Med.).
197341, Russia, St. Petersburg, Akkuratova St., 2.
E. L. Zaslavskaya
Federal State Budgetary Educational Institution of Higher Education «Academician I.P. Pavlov First St. Petersburg State Medical University» of the Ministry of Healthcare of Russian Federation.
Russian Federation
Russian Federation
Zaslavskaya Ekaterina Leonidovna – Assistant Professor of Lang Chair of Intermediate Level Therapy.
197022, Russia, St. Petersburg, Lva Tolstogo St., 6-8.
E. I. Baranova
Federal State Budgetary Educational Institution of Higher Education «Academician I.P. Pavlov First St. Petersburg State Medical University» of the Ministry of Healthcare of Russian Federation; Federal State Budgetary Institution «Almazov National Medical Research Center» of the Ministry of Health of the Russian Federation.
Russian Federation
Russian Federation
Baranova Elena Ivanovna – Dr. of Sci. (Med.), Professor of Lang Chair of Intermediate Level Therapy, Director of Cardiovascular Disease Institute; Head of Metabolic Syndrome Research Laboratory.
197022, Russia, St. Petersburg, Lva Tolstogo St., 6-8 ; 197341, Russia, St. Petersburg, Akkuratova St., 2.
References
1. Cairns J.A. et al. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter. Canadian Journal of Cardiology. 2011;27(1):74-90.
2. Akpanova D.M., et al. The prevalence and major risk factors for atrial fibrillation. Vestnik Kazakhskogo Natsionalnogo Meditsinskogo Universiteta. 2016;2. (In Russ).
3. Chugh S.S. et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2013. С. CIRCULATIONAHA. 113.005119.
4. Serdechnaya E.V., et al. Epidemiology of atrial fibrillation. Ekologiya Cheloveka. 2006;11. (In Russ).
5. Kirchhof P., Benussi S., Kotecha D., et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal. 2016;37(7):2893–29.
6. Dzeshka M.S., Lip G.Y., Snezhitskiy V., et al. Cardiac fibrosis in patients with atrial fibrillation. JACC. 2015;66(8):943-959.
7. Chamberlain A.M., Agarwal S.K., Ambrose M. et al. Metabolic syndrome and incidence of atrial fibrillation among blacks and whites in the Atherosclerosis Risk in Communities Study. Am. Heart J. 2010;159:159-164.
8. Listopad OV, Yatsuk D.I., Baranova E.I. Incidence and causes for atrial fibrillation in patients admitted to the therapeutic clinic from 1985 to 2010. Art. Gipertenziya. 2013;19(2):109-116. (In Russ).
9. Rotar O.P., et al. Prevalence of metabolic syndrome in different cities of the Russian Federation. Rossiyskiy Kardiologicheskiy Zhurnal. 2012;2. (In Russ).
Review
For citations:
Ionin VA, Petrischeva EY, Skuridin DS, Bliznyuk OI, Ivanova AA, Filatova AE, Ma. I, Zaslavskaya EL, Baranova EI. Anticoagulant therapy and components of the metabolic syndrome in patients with atrial fibrillation in real outpatient clinical practice. Meditsinskiy sovet = Medical Council. 2019;(5):60-63. (In Russ.) https://doi.org/10.21518/2079-701X-2019-5-60-63
Views:
725
Email this article 